Supplementary table S1: Univariable analysis of different potential predictor variables for patients with progression-free survival (PFS) of < 12 months or> 12 months.

|  |  |  |  |
| --- | --- | --- | --- |
| Variables | PFS <12 (n=45) | PFS >12 (n=69) | P-value  |
| Age, years (median, range) | 64 (41-76) | 58 (34-77) | 0.04 |
| Gender Male Female | 34 (70.8%)14 (29.2%) | 55 (75.3%)18 (24.7%) | 0.67 |
| Non-Responder Yes  No | 40 (83.3%)8 (16.7%) | 35 (47.9%)38 (52.1%) | <0.01 |
| Smoking status Never Former Current Unknown | 4 (8.3%)10 (20.8%)7 (14.6%)27 (56.3%) | 11 (15.1%)16 (21.9%)17 (23.3%)29 (39.7%) | 0.87 |
| Charlson Comorbidity Index 3 4 5 6 7 Unknown | -2 (4.2%)4 (8.3%)4 (8.3%)2 (4.2%)36 (75.0%) | 2 (2.7%)10 (13.7%)6 (8.2%)3 (4.1%)-52 (71.2%) | 0.10 |
| Karnofsky Performance Score 70 80 90 100 Unknown | 1 (2.1%)3 (6.3%)7 (14.6%)1 (2.1%)36 (75.0%) | 1 (1.4%)2 (2.7%)11 (15.1%)7 (9.6%)52 (71.2%) | 0.34 |
| Tumor presentation  Primary  Recurrence Unknown | 33 (68.8%)9 (18.8%)612.5%)- | 57 (78.1%)13 (17.8%)3 (4.1%) | 0.81 |
| Clinical tumor stage T1 T2 T3 T4 Unknown  | -12 (25.0%)14 (29.2%)21 (43.8%)1 (2.1%) | 4 (5.5%)14 (19.2%)40 (54.8%)15 (20.5%)- | <0.01 |
| Extravesical extension at diagnostic imaging Positive Negative Unknown | 23 (47.9%)14 (29.2%)11 (22.9%) | 21 (28.8%)38 (52.1%)14 (19.2%) | 0.01 |
| Lymphadenopathy at diagnostic imaging Positive Negative Unknown | 26 (54.2%)12 (25.0%)10 (20.8%) | 26 (35.6%)35 (47.9%)12 (16.4%) | 0.01 |
| Hydronephrosis at diagnostic imaging Positive Negative Unknown | 20 (41.7%)19 (39.6%)9 (18.8%) | 26 (35.6%)33 (45.2%)14 (19.2%) | 0.54 |
| Hemoglobin level, mmol/L (median, range) | 8.0 (5.5-9.5) | 8.3 (5.5-10.3) | 0.15 |
| Creatinine level , μmol/L (median, range) | 86 (53-209) | 80 (46-202) | 0.30 |
| Glomerular Filtration Rate (GFR), ml/min (median, range) | 74.5 (48-109) | 76.5 (35-124) | 0.65 |
| POC regimen Cisplatin based Carboplatin based | 28 (58.3%)20 (41.7%) | 57 (78.1%)16 (21.9%) | 0.03 |
| Recurrence after cystectomy Yes No  | 37 (77.1%)11 (22.9%) | 20 (27.4%)53 (72.6%) | <0.01 |
| Last follow up status Alive, no evidence of disease Alive, with recurrent disease Dead of non-disease Dead of disease Lost to follow up | 3 (6.3%)5 (10.4%)6 (12.5%)30 (62.5%)4 (8.3%) | 50 (68.5%)4 (5.5%)3 (4.1%)14 (19.2%)2 (2.7%) | <0.01 |
| Time to surgery, months (median, range) | 5 (3-10) | 5 (2-19) | 0.75 |
| Time from POC to surgery, months (median, range) | 3 (1-6) | 3 (2-9) | 0.28 |
| CR, complete response; NR, non-response; PR, partial response; POC, pre-operative chemotherapy  |

Supplementary table S2: Univariable analysis of different potential predictor variables for patients with an overall survival (OS) of < 12 months vs > 12 months.

|  |  |  |  |
| --- | --- | --- | --- |
| Variables | OS <12 (n=29) | OS >12 (n=94) | P-value  |
| Age, years (median, range) | 63 (41-73) | 60 (34-77) | 0.44 |
| Gender Male Female | 20 (69.0%)9 (31.0%) | 71 (75.5%)23 (24.5%) | 0.48 |
| Non-Responder Yes  No | 25 (86.2%)4 (13.8%) | 52 (55.3%)42 (44.7%) | <0.01 |
| Smoking status Never Former Current Unknown | 3 (10.3%)7 (24.1%)4 (13.8%)15 (51.7%) | 12 (12.8%)21 (22.3%)20 (21.3%)41 (43.6%) | 0.93 |
| Charlson Comorbidity Index 3 4 5 6 7 Unknown | -1 (3.4%)2 (6.9%)3 (10.3%)1 (3.4%)22 (75.9) | 2 (2.1%)12 (12.8%)8 (8.5%)5 (5.3%)1 (1.1%)66 (70.2%) | 0.31 |
| Karnofsky Performance Score 70 80 90 100 Unknown | -2 (6.9%)4 (13.8%)1 (3.4%)22 (75.9%) | 2 (2.1%)3 (3.2%)14 (14.9%)9 (9.6%)66 (70.2%) | 0.54 |
| Tumor presentation  Primary  Recurrence Unknown | 21 (72.4%)5 (17.2%)3 (10.3%) | 70 (74.5%)18 (19.1%)6 (6.4%) | 1.00 |
| Clinical tumor stage T1 T2 T3 T4 Unknown  | -9 (31.0%)8 (27.6%)12 (41.4%- | 4 (4.3%)18 (19.1%)46 48.9%)25 (26.6%)1 (1.1%) | 0.09 |
| Extravesical extension at diagnostic imaging Positive Negative Unknown | 11 (37.9%)11 (37.9%)7 (24.1%) | 34 (36.2)42 (44.7%)18 (19.1%) | 0.81 |
| Lymphadenopathy at diagnostic imaging Positive Negative Unknown | 20 (69.0%)3 (10.3%)6 (20.7%) | 32 (34.0%)46 (48.9%)16 (17.0%) | <0.01 |
| Hydronephrosis at diagnostic imaging Positive Negative Unknown | 11 (37.9%)13 (44.8%)5 (17.2%) | 35 (37.2%)41 (43.6%)18 (19.1%) | 1.00 |
| Hemoglobin level, mmol/L (median, range) | 7.7 (5.5-9.5) | 8.3 (5.5-10.3) | 0.03 |
| Creatinine level , μmol/L (median, range) | 79 (53-138) | 82 (46-209) | 0.78 |
| Glomerular Filtration Rate (GFR), ml/min (median, range) | 74.5 (48-109) | 78 (35-124) | 0.68 |
| POC regimen Cisplatin based Carboplatin based | 19 (65.5%)10 (34.5% | 68 (72.3%)26 (27.7%) | 0.49 |
| Recurrence after cystectomy Yes No | 11 (37.9%)18 (62.1%) | 39 (41.5%)55 (58.5%) | 0.06 |
| Last follow up status Alive, no evidence of disease Alive, with recurrent disease Dead of non-disease Dead of disease Lost to follow up | 2 (6.9%)-6 (20.7%)18 (62.1%)3 (10.3%) | 53 (56.4%)9 (9.6%)3 (3.2%)26 (27.7%)3 (3.2%) | <0.01 |
| Time to surgery, months (median, range) | 5 (3-7) | 5 (2-19) | 0.40 |
| Time from POC to surgery, months (median, range) | 3 (1-5) | 3 (2-9) | 0.68 |
| CR, complete response; NR, non-response; PR, partial response; POC, pre-operative chemotherapy  |